Detection of PAR in the CSF of patients with Parkinson's disease
AssigneeThe Johns Hopkins University
InventorsTed Dawson, Valina Dawson, Tae-In Kam, Liana Rosenthal, Shaida Andrabi
Life of this patent
Estimating the term…
Abstract
Poly(ADP-ribose) (PAR) is a protein implicated in numerous neurodegenerative disease states including Parkinson's disease (PD). To date, no routine laboratory test has been developed to diagnosis, assess or monitor patients suffering from PD. Disclosed herein a novel method to assess the PAR concentration in the cerebral spinal fluid (CSF) of a patient and correlate that concentration to the medical condition of a patient with PD. Also disclosed is the use of PAR as a biomarker for PD.
Claims10
A method for monitoring disease progression of a patient with Parkinson's disease (PD) comprising:
- a) measuring a first poly (ADP-ribose) (PAR) concentration in a first sample of cerebrospinal fluid (CSF) from a patient;
- b) administering to the patient a first medical treatment for PD;
- c) subsequent to a) and b), measuring a second PAR concentration in a second sample of CSF from the patient;
- and
- d) continuing administering the first medical treatment for PD to the patient when the second PAR concentration is the same or lower than the first PAR concentration, or administering a second medical treatment for PD to the patient when the second PAR concentration is higher than the first PAR concentration,
- wherein an increase in PAR concentration in CSF is indicative of disease progression, and
- wherein the first medical and the second medical treatment for PD are selected from the group consisting of surgery, levodopa, dopamine agonists, amantadine, anticholinergics, COMT inhibitors, MAO-B inhibitors and PARP1 inhibitors, thereby monitoring disease progression.
Dependencies are inferred from the claim text.